tiprankstipranks
Aclaris Therapeutics (GB:0H8T)
LSE:0H8T
UK Market
0H8T
Aclaris Therapeutics
RESEARCH TOOLSreports

Aclaris Therapeutics (0H8T) Share Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

0H8T Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Aclaris
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0H8T Stock 12 Month Forecast

Average Price Target

$12.00
▲(100.67% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Aclaris Therapeutics in the last 3 months. The average price target is $12.00 with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 100.67% change from the last price of $5.98.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.99,6.76,7.53,8.3,9.07,9.84,10.61,11.38,12.15,12.92,13.690000000000001,14.46,15.23,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.99,6.452307692307692,6.914615384615384,7.376923076923077,7.8392307692307694,8.301538461538462,8.763846153846155,9.226153846153846,9.688461538461539,10.150769230769232,10.613076923076923,11.075384615384616,11.537692307692307,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.99,6.298461538461539,6.606923076923077,6.915384615384616,7.223846153846154,7.532307692307692,7.840769230769231,8.149230769230769,8.457692307692309,8.766153846153847,9.074615384615385,9.383076923076924,9.691538461538462,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.94,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.861,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.535,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.662,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.991,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.677,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.031,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.041,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.402,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.342,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.345,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.99,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$16.00Average Price Target$12.00Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on GB:0H8T
Edward Nash
Canaccord Genuity
Canaccord Genuity
$10
Buy
67.22%
Upside
Initiated
09/01/26
Aclaris Therapeutics initiated with a Buy at CanaccordAclaris Therapeutics initiated with a Buy at Canaccord
Piper Sandler Analyst forecast on GB:0H8T
Biren Amin
Piper Sandler
Piper Sandler
$11
Buy
83.95%
Upside
Reiterated
08/31/26
Piper Sandler Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
H.C. Wainwright Analyst forecast on GB:0H8T
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$16
Buy
167.56%
Upside
Reiterated
08/10/26
Ram Selvaraju Reiterates Buy on Aclaris Therapeutics, Maintains $16 12-Month Price Target Amid Advancing Inflammatory Disease Pipeline
Craig-Hallum Analyst forecast on GB:0H8T
Adam Vogel
Craig-Hallum
Craig-Hallum
$10
Buy
67.22%
Upside
Reiterated
08/06/26
Craig-Hallum Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
LifeSci Capital Analyst forecast on GB:0H8T
Kate Dellorusso
LifeSci Capital
LifeSci Capital
$13
Buy
117.39%
Upside
Reiterated
08/06/26
Aclaris Therapeutics: Buy Rating Reiterated on Differentiated Pipeline and Extended Runway; $13 Price Target Maintained
Guggenheim Analyst forecast on GB:0H8T
Seamus Fernandez
Guggenheim
Guggenheim
$12
Buy
100.67%
Upside
Reiterated
05/11/26
Guggenheim Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)
Stifel Nicolaus Analyst forecast on GB:0H8T
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$4
Hold
-33.11%
Downside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Medline (NASDAQ: MDLN), Aclaris Therapeutics (NASDAQ: ACRS) and Alkermes (NASDAQ: ALKS)
Wedbush Analyst forecast on GB:0H8T
Martin Fan
Wedbush
Wedbush
$10
Buy
67.22%
Upside
Reiterated
05/08/26
Analysts' Top Healthcare Picks: Silence Therapeutics (SLN), Aclaris Therapeutics (ACRS)
Oppenheimer Analyst forecast on GB:0H8T
Jeff Jones
Oppenheimer
Oppenheimer
$10
Buy
67.22%
Upside
Reiterated
05/08/26
Aclaris Therapeutics (ACRS) Gets a Buy from Oppenheimer
Goldman Sachs Analyst forecast on GB:0H8T
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$10
Buy
67.22%
Upside
Reiterated
04/16/26
Goldman Sachs Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
Leerink Partners Analyst forecast on GB:0H8T
Thomas Smith
Leerink Partners
Leerink Partners
$7
Buy
17.06%
Upside
Reiterated
10/15/25
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Aclaris Therapeutics (NASDAQ: ACRS)
Cantor Fitzgerald Analyst forecast on GB:0H8T
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
10/15/25
Cantor Fitzgerald Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on GB:0H8T
Edward Nash
Canaccord Genuity
Canaccord Genuity
$10
Buy
67.22%
Upside
Initiated
09/01/26
Aclaris Therapeutics initiated with a Buy at CanaccordAclaris Therapeutics initiated with a Buy at Canaccord
Piper Sandler Analyst forecast on GB:0H8T
Biren Amin
Piper Sandler
Piper Sandler
$11
Buy
83.95%
Upside
Reiterated
08/31/26
Piper Sandler Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
H.C. Wainwright Analyst forecast on GB:0H8T
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$16
Buy
167.56%
Upside
Reiterated
08/10/26
Ram Selvaraju Reiterates Buy on Aclaris Therapeutics, Maintains $16 12-Month Price Target Amid Advancing Inflammatory Disease Pipeline
Craig-Hallum Analyst forecast on GB:0H8T
Adam Vogel
Craig-Hallum
Craig-Hallum
$10
Buy
67.22%
Upside
Reiterated
08/06/26
Craig-Hallum Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
LifeSci Capital Analyst forecast on GB:0H8T
Kate Dellorusso
LifeSci Capital
LifeSci Capital
$13
Buy
117.39%
Upside
Reiterated
08/06/26
Aclaris Therapeutics: Buy Rating Reiterated on Differentiated Pipeline and Extended Runway; $13 Price Target Maintained
Guggenheim Analyst forecast on GB:0H8T
Seamus Fernandez
Guggenheim
Guggenheim
$12
Buy
100.67%
Upside
Reiterated
05/11/26
Guggenheim Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)
Stifel Nicolaus Analyst forecast on GB:0H8T
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$4
Hold
-33.11%
Downside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Medline (NASDAQ: MDLN), Aclaris Therapeutics (NASDAQ: ACRS) and Alkermes (NASDAQ: ALKS)
Wedbush Analyst forecast on GB:0H8T
Martin Fan
Wedbush
Wedbush
$10
Buy
67.22%
Upside
Reiterated
05/08/26
Analysts' Top Healthcare Picks: Silence Therapeutics (SLN), Aclaris Therapeutics (ACRS)
Oppenheimer Analyst forecast on GB:0H8T
Jeff Jones
Oppenheimer
Oppenheimer
$10
Buy
67.22%
Upside
Reiterated
05/08/26
Aclaris Therapeutics (ACRS) Gets a Buy from Oppenheimer
Goldman Sachs Analyst forecast on GB:0H8T
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$10
Buy
67.22%
Upside
Reiterated
04/16/26
Goldman Sachs Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
Leerink Partners Analyst forecast on GB:0H8T
Thomas Smith
Leerink Partners
Leerink Partners
$7
Buy
17.06%
Upside
Reiterated
10/15/25
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Aclaris Therapeutics (NASDAQ: ACRS)
Cantor Fitzgerald Analyst forecast on GB:0H8T
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
10/15/25
Cantor Fitzgerald Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
DNLIDenali Therapeutics
SNDXSyndax Pharmaceuticals
ZYMEZymeworks
PTGXProtagonist Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aclaris Therapeutics

3 Months
Ram SelvarajuH.C. Wainwright
Success Rate
12/12 ratings generated profit
100%
Average Return
+47.10%
Copying Ram Selvaraju's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +47.10% per trade.
1 Year
Ram SelvarajuH.C. Wainwright
Success Rate
12/12 ratings generated profit
100%
Average Return
+142.06%
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +142.06% per trade.
2 Years
Ram SelvarajuH.C. Wainwright
Success Rate
12/12 ratings generated profit
100%
Average Return
+162.88%
Copying Ram Selvaraju's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +162.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0H8T Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
17
16
10
7
7
Buy
0
0
0
0
0
Hold
1
1
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
17
11
7
7
In the current month, 0H8T has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0H8T average Analyst price target in the past 3 months is 12.00.
Each month's total comprises the sum of three months' worth of ratings.

0H8T Financial Forecast

0H8T Earnings Forecast

Next quarter’s earnings estimate for 0H8T is -$0.17 with a range of -$0.21 to -$0.15. The previous quarter’s EPS was -$0.15. 0H8T beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0H8T has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0H8T is -$0.17 with a range of -$0.21 to -$0.15. The previous quarter’s EPS was -$0.15. 0H8T beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0H8T has Performed in-line its overall industry.

0H8T Sales Forecast

Next quarter’s sales forecast for 0H8T is $1.30M with a range of $0.00 to $2.05M. The previous quarter’s sales results were $1.63M. 0H8T beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0H8T has Performed in-line its overall industry.
Next quarter’s sales forecast for 0H8T is $1.30M with a range of $0.00 to $2.05M. The previous quarter’s sales results were $1.63M. 0H8T beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0H8T has Performed in-line its overall industry.

0H8T Stock Forecast FAQ

What is GB:0H8T’s average 12-month price target, according to analysts?
Based on analyst ratings, Aclaris Therapeutics’s 12-month average price target is 12.00.
    What is GB:0H8T’s upside potential, based on the analysts’ average price target?
    Aclaris Therapeutics has 100.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Aclaris Therapeutics a Buy, Sell or Hold?
          Aclaris Therapeutics has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Aclaris Therapeutics’s share price target?
            The average share price target for Aclaris Therapeutics is 12.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $16.00 ,and the lowest forecast is $10.00. The average share price target represents 100.67% Increase from the current price of $5.98.
              What do analysts say about Aclaris Therapeutics?
              Aclaris Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Aclaris Therapeutics?
                To buy shares of GB:0H8T, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.